Danielle Gullette, APRN
Family · Monroe, LANPI 1821764440
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 24.8% of the total. 2025 is the largest year on record at $2,901, more than ten times the $34 reported in 2021. Among family clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Sanofi$586
- Boehringer Ingelheim$522
- Insmed, Inc.$394
- Regeneron Healthcare Solutions, Inc.$308
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,81299%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,458 |
| GSK | 66 | $1,174 |
| Sanofi | 19 | $586 |
| Boehringer Ingelheim | 28 | $522 |
| Insmed, Inc. | 23 | $394 |
| Regeneron Healthcare Solutions, Inc. | 10 | $308 |
| Verona Pharma, Inc. | 12 | $250 |
| Actelion Pharmaceuticals US, Inc. | 14 | $242 |
| Viatris Specialty LLC | 10 | $202 |
| Grifols USA, LLC | 10 | $176 |
| Inogen, Inc. | 10 | $116 |
| Baxter Healthcare | 5 | $111 |
| AbbVie | 3 | $83 |
| Amgen | 3 | $52 |
| Philips North America LLC | 3 | $49 |
| Mylan Specialty L.p. | 3 | $47 |
| Itamar Medical Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,879 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 584 | $396,571 |
| Spiriva RespimatTiotropium Bromide | 245 | $130,364 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 110 | $74,275 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 60 | $36,194 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 62 | $27,605 |
| EliquisApixaban | 25 | $18,964 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $18,324 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 543 | $17,177 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $15,717 |
| Spiriva HandihalerTiotropium Bromide | 18 | $8,703 |
| Arnuity ElliptaFluticasone Furoate | 27 | $6,333 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $4,893 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $4,562 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,510 |
| DuleraMometasone/Formoterol | 14 | $4,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,174 | $453,343727 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat, Striverdi Respimat | $522 | $185,896349 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,458 | $79,168132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Monroe
- Rebecca HoodMonroe$15K
- Gabrielle NicolleMonroe$14K
- Catherine MidyettMonroe$13K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.